Autologous stem cell therapy for acute myocardial infarction with severe systolic dysfunction – protocol and feasibility at 1 month follow-up – Bucharest experience

November 17, 2014

	Read full article
Article Title:	Autologous stem cell therapy for acute myocardial infarction with severe systolic dysfunction – protocol and feasibility at 1 month follow-up – Bucharest experience
Authors:	Micheu M., Oprescu N., Calmac L., Pitic D., Dorobantu M.
Affiliation:	Department of Cardiology, Clinical Emergency Hospital of Bucharest
Abstract:	Our aim was to assess the feasibility and safety within first month after autologous bone marrow stem cell therapy in patients with acute myocardial infarction (AMI) and severe systolic dysfunction. Twelve patients were included. All the patients were treated in accordance with existing guidelines. In the stem cell treated group, collection of 50 ml of bone marrow aspirate was performed; after density gradient separation, the mononuclear bone marrow cell suspension was delivered via intracoronary route. At 1 month follow-up, there were no significant differences between groups regarding systemic inflammatory response, malignant arrhythmias or deaths. Moreover, in stem cell treated group we observed an antiremodelling effect along with improvement of left ventricle systolic function. The autologous bone marrow stem cell therapy has proven to be a feasible and safe method of treatment, but larger studies are required in order to reveal the intimate mechanisms of action.
Keywords:	autologous bone marrow stem cells, acute myocardial infarction, left ventricular systolic function, MACE, left ventricular volumes.
References:
*Correspondence:	Dr. Miruna Micheu, Department of Cardiology, Clinical Emergency Hospital of Bucharest, email:mirunamicheu@yahoo.com

About The Author

dti